- £187.52bn
- £208.44bn
- $45.81bn
- 80
- 12
- 97
- 70
REG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Farxiga extended in the US for heart failure
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - ODAC vote on Lynparza combo in prostate cancer
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - Board Committee Changes
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Update to arrangements with Sobi and Sanofi
AnnouncementREG - AstraZeneca PLC - Lynparza + Imfinzi met endpoint in ovarian cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Ultomiris recommended for NMOSD EU approval
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - AstraZeneca completes KYM agreement for CMG901
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi improved EFS in resectable lung cancer
Announcement